Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986454 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Administration of BMS-986454 | EXPERIMENTAL | - |
| Part A: Placebo | PLACEBO_COMPARATOR | - |
| Part B: Administration of BMS-986454 | EXPERIMENTAL | - |
| Part B: Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986454 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Participants with Rheumatoid Arthritis must have onset after age 18. * Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA. * Participants must have evidence of swelling in at least 1 joint o...
Top 20 of 31 competitors
BMS-986454 is an investigational small molecule drug being developed by Bristol-Myers Squibb Company (BMY) for the treatment of rheumatoid arthritis. It is currently in Phase 1 clinical development and has not been approved by the FDA. It is designed to target CD19.
BMS-986454 is being studied for use in rheumatoid arthritis, an autoimmune condition affecting the joints. The only clinical trial of BMS-986454 to date enrolls participants with rheumatoid arthritis. It remains investigational and is not approved for any indication.
BMS-986454 targets CD19. CD19 is a protein found on the surface of B cells, and targeting it is intended to modulate the B cell driven immune response implicated in rheumatoid arthritis. Bristol-Myers Squibb is evaluating this small molecule in a Phase 1 study.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer of BMS-986454. The company is running the Phase 1 clinical program for the drug in rheumatoid arthritis.
BMS-986454 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is evaluating the drug in participants with rheumatoid arthritis.
BMS-986454 is being studied in one clinical trial, NCT07171983, titled A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis. The trial is a recruiting, randomized, double-blind, placebo-controlled Phase 1 study with an planned enrollment of 46 participants in India.